Qiagen acquires AmniSure, accesses pregnancy assay

May 2012
Medical Device Daily;5/7/2012, Vol. 16 Issue 88, p2
The article reports on the acquisition by Qiagen of AmniSure International, a firm that produces an assay for determining whether a pregnant woman is suffering rupture of fetal membranes (ROM). For 2012, the transaction is expected by Qiagen to contribute 12 million U.S. dollars to the firm and 24 million U.S. dollars in full-year sales by 2013. Qiagen Chief Executive Officer (CEO) Peer Schatz says the AmniSure assay is a significant addition to their portfolio of tests.


Related Articles

  • Qiagen offers $101 million for 47% stake in Ipsogen.  // Medical Device Daily;6/17/2011, Vol. 15 Issue 112, p2 

    The article focuses on the plan of Qiagen to acquire a 47% stake in Ipsogen. The acquisition deal, valued at 101 million U.S. dollars, would provide Qiagen access to wide range of assays covering several biomakers. According to Peer Schatz of Qiagen, the deal would further expand the company's...

  • Deals roundup.  // Medical Device Daily;10/1/2009, Vol. 13 Issue 189, p7 

    The article reports on the acquisition of DxS, a privately-held developer and manufacturer of companion diagnostic products, by Qiagen. With the acquisition, Qiagen believes it has taken a strong leadership position in the personalized health care. According to Qiagen, the combined company is...

  • QIAGEN Completes Acquisition of Cellestis Limited.  // Worldwide Biotech;Oct2011, Vol. 23 Issue 10, p4 

    The article reports on the acquisition by Qiagen of Cellestis Limited. According to Peter M. Schiatz of Qiagen, the integration process will be started after completing the transaction. Information on the QuantiFERON® technology of Cellestis is presented. Qiagen is a holding company based in...

  • DxS Acquisition Boosts Qiagen's Companion Diagnostics Portfolio.  // BioWorld Today;9/24/2009, Vol. 20 Issue 184, p2 

    The article reports on the acquisition of DxS Ltd. by Qiagen NV, a company known for selling sample and assay products. With the acquisition of DxS Ltd., the company will now have in its diagnostics portfolio the TheraScreen companion diagnostic kits. In addition, DxS is a partner of Eli Lilly...

  • Qiagen buys 61% of Ipsogen, beefs up its Cellestis offer.  // Medical Device Daily;7/12/2011, Vol. 15 Issue 128, p2 

    The article reports on the acquisition by Qiagen of 61% of Ipsogen, a developer of molecular profiling and personalized healthcare diagnostics for a wide range of applications in the hematology field.

  • Qiagen completes Digene buy; ME buys stroke treatment rights.  // Medical Device Daily;8/1/2007, Vol. 11 Issue 145, p2 

    The article reports on the completion of the acquisition of Digene by Qiagen of the Netherlands. Report says that Qiagen has completed the acquisition through a tender offer and subsequent merger of Digene with and into a wholly owned subsidiary of the company. Under the deal, Digene will become...

  • Qiagen's shareholders okay $1.6 billion merger with Digene.  // Medical Device Daily;7/23/2007, Vol. 11, p6 

    The article announced that Qiagen has received the vote of the necessary percentage of its shareholders in favor of the $1.6 billion acquisition of Digene at its extraordinary general meeting of shareholders held in the Netherlands. The companies reported that they had entered into a merger...

  • Rapigene bargain buy for Qiagen. Hodgson, John // Nature Biotechnology;Feb2000, Vol. 18 Issue 2, p132 

    Reports on the acquisition of the genomic analysis company Rapigene by the biotechnology company Qiagen NV. Factors which led to the acquisition of the genomic analysis company; Owner of Rapigene prior to the acquisition.

  • Qiagen now boasting extra Ingenuity after acquisition.  // Scientific Computing World;Jun/Jul2013, Issue 130, p4 

    The article reports on the acquisition of U.S.-based Ingenuity Systems Inc., provider of software solutions, by Qiagen NV, provider of sample and assay technologies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics